メニュー
Provides a monitoring schedule for patients receiving GnRH agonist therapy for pubertal suppression. Trigger phrases include 'patient undergoing GnRH agonist therapy' or 'initiating pubertal suppression'.
デフォルトでは、最初にソースを確認する Prompt が選択されています。直接コマンドに切り替えるか、ローカルコピーをダウンロードすることもできます。
インストールを決める前に、SKILL.md と SkillsMP に表示されている付属ファイルをお読みください。
SOC 職業分類に基づく
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
直接コマンドでは確認用 Prompt が省略されます。実行前にソースを確認してください。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill es-follow-pubertal-suppression-monitoringコマンドは1行のまま表示されます。コピー前に横へスクロールして全体を確認してください。
ローカルで確認しますか？SkillsMP が現在取得できるファイルをダウンロードできます。
SKILL.md を表示中
For a person with confirmed islet autoantibodies (early-stage type 1 diabetes), state the numerical progression risk to Stage 3 T1D by stage and age, set the age-stratified monitoring frequency (metabolic and HbA1c), apply the ≥10% longitudinal HbA1c rise → OGTT rule, and give the standard risk-modifier and communication framing. Use when a clinician asks how often should I monitor this Stage 1 child, what's the risk of this teenager progressing to insulin, adult with GAD positive what's the 5-year risk, my patient's HbA1c has risen 12% is that important, single autoantibody how often to retest, or how to counsel a family about progression risk. Grounded in Phillip et al. Diabetologia 2024 international staging and monitoring consensus, cross-referenced with Hussain et al 2026 IDF Europe roadmap.
Order and confirm islet autoantibody screening for early-stage type 1 diabetes — which antibodies to test (GAD65, IAA, IA2, ZnT8), sample types (capillary dried blood spot, venous), the mandatory two-sample two-method confirmation protocol, and how to interpret a positive, negative, or single-antibody result. Use when a clinician asks how to screen for early T1D, which islet autoantibodies to order, how to confirm a positive T1D antibody screen, is one autoantibody enough for T1D diagnosis, GAD antibody positive what next, or is running a general population or family-history T1D screening program. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
Classify a person with a positive islet autoantibody screen into a specific stage of type 1 diabetes (At Risk / Stage 1 / Stage 2a / Stage 2b / Stage 3a / Stage 3b / Stage 4) using the international consensus staging framework based on autoantibody count and glycaemic status. Use when a clinician asks how to stage a positive autoantibody screen, what stage of T1D is this, is this early-stage T1D, does this child need insulin yet, is this presymptomatic T1D, does this qualify for teplizumab, or presents a person with any combination of islet autoantibodies + glucose data. Applies across paediatric and adult populations. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
| name | es-follow-pubertal-suppression-monitoring |
| description | Provides a monitoring schedule for patients receiving GnRH agonist therapy for pubertal suppression. Trigger phrases include 'patient undergoing GnRH agonist therapy' or 'initiating pubertal suppression'. |
Collect baseline and follow-up data: every 3–6 months measure height, weight, sitting height, blood pressure, and Tanner stages; every 6–12 months obtain LH, FSH, estradiol/testosterone, and 25OH vitamin D; every 1–2 years perform DXA bone density and left-hand X-ray for bone age if clinically indicated.
Assess Tanner stage progression and laboratory markers (LH, FSH, estradiol/testosterone). If no Tanner advancement and LH/FSH are at prepubertal levels with sex steroids suppressed → Rule In (adequate suppression). Otherwise → Rule Out (inadequate suppression).
For adequate suppression, classify as stable and continue routine monitoring; for inadequate suppression, classify as non‑suppressed and trigger adherence evaluation and dose reassessment.
If stable: maintain current GnRH agonist dose and follow‑up schedule. If non‑suppressed: verify adherence, consider dose increase, investigate causes (e.g., drug interactions, metabolism), and repeat assessment in 1–3 months.
Do not rely on Tanner stages alone without corroborating LH/FSH and sex steroid levels; do not omit vitamin D assessment in patients with limited sun exposure or malabsorption; avoid delaying bone density monitoring beyond 2‑year intervals in those with risk factors for osteoporosis; do not overlook psychosocial stressors that may affect medication adherence; never adjust GnRH agonist dose based solely on symptomatic changes without laboratory confirmation.
A 13‑year‑old transgender female starts leuprolide 3.75 mg SC monthly. At 4‑month visit, Tanner breast stage remains G2, LH is 0.2 IU/L, estradiol is 5 pg/mL. Assessment rules in adequate suppression; she continues the same dose with repeat labs and Tanner staging in 3 months.
Source: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, https://doi.org/10.1210/jc.2017-01658